Researchers at ABSORB Japan found that patients undergoing percutaneous coronary intervention (PCI) showed similar results using drug-eluting coronary stent or ‘scaffolds’ produced from bioresorbable material as compared to using metal stent. A study conducted by ABSORB included 400 participants of an average age 67.2 years. 266 of patients out of 400 underwent PCI using bioresorbable stent and remaining through metal stents. Both of the types were coated with Everolimus to prevent re-blockage of the artery.
Metal stent is a material used in production of vascular stents. It is primarily used for cardiovascular diseases and vessel related blockages. Target lesion failure was the primary endpoint of the study at one year. It occurred in 4.2% of the patients with bioresorbable vascular scaffolds (BVS) and 3.8% of the patients with metal stents indicating non-inferiority of BVS. The second endpoint was at 13 months, which was angiographic in-segment late lumen loss (LLL). Again, the results showed non-inferiority of BVS. The study was conducted to support regulatory approval for BVS in Japan.
Dr. Takeshi Kimura, PhD, from Kyoto University Hospital, Kyoto, Japan said, "These results support the feasibility of BVS to potentially improve the long-term outcomes of patients, BVS demonstrated a similar 12-month clinical safety and efficacy profile as the metal stent, with comparable 13-month angiographic outcomes. These results are consistent with a few previous studies reporting either 12-month clinical outcome or 9-month angiographic outcome, supporting the feasibility of BVS use to potentially improve the long-term outcomes of patients undergoing PCI."
Many reports have been published analyzing the changing market status of diabetes devices industry. Recently, Prof Research Reports has added a report titled “2015 Vascular Stent Industry Report - Global and Chinese Market Scenario.” The report offers an extensive analysis of production information, key manufacturers, industry chain structure, and investment feasibility studies of the global vascular stent industry with a spotlight on Chinese market.